Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

Orphanet Journal of Rare Diseases

Volumn 10, Issue , 2015, Pages 1-2

  Gillmore, Julian D ^a   Falk, Rodney H ^b   Maurer, Mathew S ^c   Hanna, Mazen ^d   Karsten, Verena ^e   Vest, John ^e   Gollob, Jared ^e   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c New York Presbyterian Medical Center at Columbia   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e ALNYLAM PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN; REVUSIRAN; TROPONIN I; TROPONIN T;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEART AMYLOIDOSIS; HUMAN; INTERVENTRICULAR SEPTUM; NEW YORK HEART ASSOCIATION CLASS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; RNA INTERFERENCE;

EID: 84992110587     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-10-S1-O21     Document Type: Article

References (0)